IP Library Granted Patent US 8,552,158
Granted Patent B2
US 8,552,158 · App. 12/438,154 · Granted Oct 8, 2013

Method for the production of insulin-like growth factor-1

Inventors: Stephan Fischer (Polling, DE); Friederike Hesse (Munich, DE); Hendrik Knoetgen (Penzberg, DE); Kurt Lang (Penzberg, DE); Joerg Thomas Regula (Munich, DE); Christian Schantz (Munich, DE); Andreas Schaubmar (Penzberg, DE)
Assignee: Hoffmann-La Roche Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,552,158
App. No.
12/438,154
Granted
Oct 8, 2013
Kind
B2
Abstract

Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

Claims (14)

1. A method for the production of IGF-I, said method comprising:

a) cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Arg-Pro, and Pro-Arg-Pro, and

b) recovering and cleaving said fusion protein with IgA protease to recover said IGF-I.

2. The method of claim 1 , wherein said IGF-I is selected from the group consisting of: IGF-I (SEQ ID NO:1), an IGF-I SEQ ID NO: 1, in which at the C-terminus 3-6 amino acids are deleted, IGF-I of SEQ ID NO. 1, in which at amino acid position 36 arginine is substituted by alanine, and IGF-I of SEQ ID NO. 1 , in which at amino acid position 37 arginine is substituted by alanine.

3. The method of claim 1 , wherein said IGF-I is C-terminally linked to human Fc from IgG.

4. The method of claim 1 , wherein said propeptide has the following amino acid sequence:

Met-X 1 -His n -X 2 -Y-Pro-, wherein

Met denotes methionine,

X 1 is a bond, serine or asparagine,

His is histidine,

n is a number from 0 to 6,

X 2 is a linker peptide, selected from the group consisting of peptides SEQ ID NO: 6-10,

Pro is proline, and

Y is selected from the group consisting of Pro, Pro-Ala, Arg-Pro, and Pro-Arg-Pro.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2010
From: FISCHER, STEPHAN; HESSE, FRIEDERIKE; KNOETGEN, HENDRIK; LANG, KURT; REGULA, JOERG THOMAS; SCHANTZ, CHRISTIAN; SCHAUBMAR, ANDREAS
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 024003/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2010
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE, INC.
Reel/Frame 024003/0990 →
Priority Claims (1)
EP 06018171 · Aug 31, 2006 · regional
Continuity (1)
Related Publication 20100121036A1 · May 13, 2010